Denileukin diftitox
| Clinical data | |
|---|---|
| Trade names | Ontak, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611024 |
| License data | |
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 70-80 min |
| Identifiers | |
| |
| CAS Number | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C2560H4042N678O799S17 |
| Molar mass | 57647.46 g·mol−1 |
| | |
| Clinical data | |
|---|---|
| Pronunciation | DEH-nih-LOO-kin DIF-tih-tox |
| Trade names | LYMPHIR |
| Other names | E7777; formerly I/ONTAK; DAB389IL-2 (historical) |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a611024 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous infusion |
| Drug class | IL-2 receptor-directed cytotoxin; antineoplastic immunotoxin |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 100% by intravenous administration |
| Protein binding | Not formally characterized |
| Metabolism | Proteolytic degradation |
| Elimination half-life | Approximately 112 minutes, cycle 1 terminal |
| Excretion | Proteolytic degradation |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Molar mass | 58 kDa recombinant fusion protein |
Denileukin diftitox, sold under the brand name Ontak from 1999-2014, was an anti-cancer medication approved for the treatment of adults with T-cell lymphoma. It is an IL2-receptor-directed cytotoxin. It is an engineered protein combining interleukin-2 and diphtheria toxin.
Denileukin diftitox-cxdl, sold under the brand name LYMPHIR, is an interleukin-2 (IL-2) receptor–directed cytotoxin (immunotoxin) used to treat cutaneous T-cell lymphoma (CTCL). It is a recombinant fusion protein that combines an IL-2 ligand with a fragment of diphtheria toxin.
In 2024, the U.S. Food and Drug Administration (FDA) approved denileukin diftitox-cxdl in the United States. for the treatment of adults with relapsed or refractory stage I–III CTCL after at least one prior systemic therapy. Denileukin diftitox-cxdl is administered by intravenous infusion.
A prior formulation of denileukin diftitox (marketed as Ontak) was approved in 1999 and was voluntarily withdrawn from the U.S. market in 2014. In 2021, the current more bioactive formulation was also approved in Japan.